Electrogram-Guided Myocardial Advanced Phenotyping (The eMAP Trial)
Trial Snapshot
- Phase
- Not Applicable
- Status
- Terminated
- Sponsor
- University of Pennsylvania
- Enrollment
- 35
- Locations
- 2
- Primary Endpoint
- Fluoroscopy guided EMB and EAM guided EMB on all patients meeting existing guidelines for biopsy.
Study Overview
Brief Summary
Fluoroscopy guided EMB and EAM guided EMB on all patients meeting existing guidelines for biopsy.
Detailed Description
Non-Ischemic Cardiomyopathy (NICM) is a common cause of heart failure (HF) and death. NICM is a heterogeneous entity, and specific etiologies are infrequently identified. In part due to limited disease characterization, specific treatments are lacking for most of the different underlying causes of NICM. Depending on the cohort, 30-70 percent of patients with new-onset NICM develop persistent systolic dysfunction despite guideline-directed medical therapy, and these patients have high rates of subsequent morbidity and resource utilization.
Current guidelines support the use of endomyocardial biopsy (EMB) in patients with both new-onset and persistent cardiomyopathy. However, EMB is underutilized in these populations due to its low diagnostic yield. A combination of sampling error resulting from standard fluoroscopy-guided EMB in disease entities with patchy myocardial involvement and rudimentary tissue phenotyping of the specimens which are obtained contribute to this low diagnostic yield. In recent years, there has been increasing interest in the use of electro-anatomic mapping (EAM) to help identify areas of myocardium with discrete pathology based on abnormalities in intra-cardiac electrogram voltage and morphologies. Therefore, the primary objective of this protocol is to provide definitive evidence that EAM-guided biopsy leads to a superior diagnostic yield compared with conventional fluoroscopy-guided biopsy in patients with new-onset and persistent NICM.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age ≥ 18 years
- •New onset NICM as defined by the presence of left ventricular dysfunction (LVEF < 45% by echocardiography and/or MRI), with symptoms or signs of HF (dyspnea, orthopnea, edema, ascites, rales or pulmonary vascular congestion on chest radiography) of less than 3 months in duration.
- •Persistent recent onset NICM as defined by the LVEF and signs/symptoms in #2 above with persistence of the LVEF < 45% despite evidence-based treatment for HF with reduced LVEF for 2 to 6 months.
- •Willingness to provide informed consent
Exclusion Criteria
- •Prior diagnosis of HF or documented LVEF < 45% more than 6 months prior to enrollment.
- •Coronary artery disease, either by history or as determined by coronary angiography demonstrating hemodynamically significant lesions deemed sufficient to potentially contribute to left ventricular dysfunction.
- •Ongoing hemodynamically significant arrhythmias deemed to be an independent cause of HF decompensation
- •Constrictive pericarditis or tamponade
- •Complex congenital heart disease
- •History of malignancy with treatment by anthracyclines or other known cardiotoxic chemotherapeutic agents
- •More than mild aortic or mitral stenosis
- •Intrinsic (prolapse, rheumatic) valve disease with severe mitral, aortic or tricuspid regurgitation
- •Primary hypertrophic cardiomyopathy
- •Untreated thyroid disease
- •Severe nutritional deficiency
- •Severe uncontrolled hypertension
- •Sepsis, active infection (excluding cystitis) or other comorbidity driving the HF decompensation
- •History of cardiac transplantation
- •Acute or chronic severe liver disease as evidenced by any of the following: encephalopathy, variceal bleeding, INR > 1.5 in the absence of anticoagulation treatment
- •Inability to comply with planned study procedures
Outcomes
Primary Outcomes
Fluoroscopy guided EMB and EAM guided EMB on all patients meeting existing guidelines for biopsy.
Time Frame: November 2018
Additional biopsies
Secondary Outcomes
No secondary outcomes reported